Srivastava A
Department of Microbiology & Immunology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis 46202-512, USA.
Curr Opin Mol Ther. 2001 Oct;3(5):491-6.
It has become increasingly clear that parvovirus-based vectors are a potentially safe and useful alternative to the more commonly used retroviral and adenoviral vectors. Parvovirus vectors have been successfully used in phase I clinical trials for gene therapy of cystic fibrosis and hemophilia B, and several salient features of these vectors provide further support to the suggestion that their use in potential gene therapy of a wide variety of human diseases is imminent and perhaps well justified.
越来越明显的是，基于细小病毒的载体是比更常用的逆转录病毒和腺病毒载体更具潜在安全性和实用性的替代选择。细小病毒载体已成功用于囊性纤维化和B型血友病基因治疗的I期临床试验，这些载体的几个显著特征进一步支持了以下观点：在多种人类疾病的潜在基因治疗中使用它们即将成为现实，而且可能是很有道理的。
